Jan 8, 2024
|
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
|
Jan 3, 2024
|
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
|
Dec 20, 2023
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Nov 21, 2023
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Nov 21, 2023
|
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
|
Nov 15, 2023
|
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
|
Nov 13, 2023
|
Ardelyx Announces Departure of Board Member
|
Nov 10, 2023
|
Ardelyx to Participate at the Jefferies London Healthcare Conference
|
Nov 6, 2023
|
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
|
Nov 3, 2023
|
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
|